KDC-MN-389 – Kodiac biolabs

Plain-language summaryIntrigue 55 / 100

Oxandrolone (Anavar, Oxandrin) is a synthetic anabolic steroid developed by Searle in 1962. The 17-alpha-alkylation makes it orally active by blocking liver breakdown, and the 2-oxa substitution shifts the profile toward anabolic (muscle-building) over androgenic (masculinizing) effects in standard assays. FDA-approved for severe weight loss after surgery, trauma, infection, or chronic illness, plus bone pain in osteoporosis. Burn recovery is the cleanest clinical use case, where AAS protocols have solid evidence. HIV wasting is another approved indication. In the gym world it is one of the most commonly diverted oral AAS because users perceive a relatively favorable side-effect profile. Schedule III. Hepatotoxic at high doses owing to the alkylation. Reference 17-alpha-alkylated oral AAS. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

Mature clinical AAS with replicated burn-recovery evidence but no novel mechanism or frontier research angle

Look, oxandrolone isnt a mystery. Searle synthesized it in 1962, the FDA approved it as Oxandrin, and its mechanism has been understood for decades. As a research compound it occupies a specific and well-defined niche: the canonical reference 17-alpha-alkylated oral AAS. That role gives it some legitimate bench value even now, but it doesnt make it an exciting primary research target.

The mechanism story is completely unsurprising. AR agonism with a higher anabolic-to-androgenic ratio than testosterone, achieved through the 2-oxa substitution at carbon-2 and the 17-alpha methyl group that confers oral activity by resisting hepatic first-pass metabolism. The Hershberger assay work defining its A:A ratio was done a long time ago. What you’re getting is a well-mapped receptor binding profile with no novel target biology, no dual or multi-target mechanism, and no new pharmacology. Single-receptor agonism in a saturated class is about as far from the frontier as you can get.

The clinical evidence is where this compound actually earns points. Burn recovery is one of the more rigorously studied applications of any AAS; pediatric burn trials and adult catabolic wasting data have been replicated across multiple institutions and form the basis of FDA approval. The HIV wasting indication is similarly evidence-backed. This isnt single-lab data or anecdote. There are genuine RCTs, modest N but replicated, and the translational signal in severe catabolic states is real. For a researcher studying anabolic signaling under physiological stress, oxandrolone is a legitimate clinical reference point with a credible evidentiary floor.

That said, nobody picking up oxandrolone for a new program is doing so because it opens a novel mechanistic door. Its differentiation within the AAS class is real but narrow: it’s the oral 17aa benchmark, the compound you reach for when you need a controlled comparison for hepatotoxicity studies or anabolic-to-androgenic ratio methodology. Thats a niche that matters, but it wont pull a lab into new territory. The interesting open questions, long-term IGF-1 modulation, interaction with the GH axis in burn patients, comparative hepatic impact of 17aa structures, are well-known to AAS specialists already and not the kind of questions attracting broad investigator interest in 2025.

What we like: FDA approval, replicated burn data, clean reference profile for comparative 17aa work. What we dont like: the mechanism has no new angles, the literature is decades old, and Schedule III classification adds real procurement and handling overhead for a compound that is unlikely to produce a surprising result. For a general research program not already invested in anabolic pharmacology, theres not much here that earns bench time over newer targets.

Novelty: 18
Mechanism promise: 22
In-category differentiation: 35
Evidence quality: 68
Translational signal: 63
Research bench value: 45

Rationale Oxandrolone scores low on novelty and mechanism because it is a fully mapped AR agonist from 1962 with no dual-target or novel pharmacology; it recovers modestly on evidence and translational signal through replicated RCTs in burn recovery and HIV wasting, and carries narrow bench value as the canonical reference 17-alpha-alkylated oral AAS. The Schedule III cap at 75 does not bind because the raw weighted score lands at 39.

17-alpha-alkylated oral anabolic steroid

A 17-alpha-alkylated synthetic anabolic steroid; clinically used in burn recovery and HIV wasting; widely used in non-medical AAS contexts.

Abstract

Oxandrolone (17-beta-hydroxy-17-alpha-methyl-2-oxa-5-alpha-androstan-3-one; CAS 53-39-4; molecular formula C19H30O3; molecular weight 306.44) is a 17-alpha-alkylated synthetic anabolic-androgenic steroid (AAS) developed by Searle in 1962 and approved by the FDA (Anavar, Oxandrin) for severe weight loss following surgery, trauma, infection, or chronic illness; for relief of bone pain in osteoporosis; and for compensation of catabolic states. Mechanism: AR agonism (lower than testosterone but with relatively higher anabolic-to-androgenic ratio in the Hershberger assay). The 2-oxa substitution and 17-alpha alkylation produce oral activity (resistance to first-pass hepatic metabolism) and a more anabolic profile relative to androgenic. Plasma half-life is approximately 9 hours. Schedule III in the US under the CSA. Used in burn recovery (where AAS clinical use is well-established) and in HIV wasting; the most commonly diverted oral AAS for non-medical bodybuilding owing to a perceived favorable side effect profile. Used as a reference 17-alpha-alkylated oral AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-389Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-389

Oxandrolone

Abstract

Read the full monograph